Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

Authors :: Ueshima, Kazuomi
Kudo, Masatoshi
Tsuchiya, Kaoru
Kato, Naoya
Yamashita, Tatsuya
Shimose, Shigeo
Numata, Kazushi
Kodama, Yuzo
Tanaka, Yasuhito
Kuroda, Hidekatsu
Itoh, Shinji
Aikata, Hiroshi
Hiraoka, Atsushi
Moriguchi, Michihisa
Wada, Yoshiyuki
Nakao, Kazuhiko
Tateishi, Ryosuke
Ogasawara, Sadahisa
Yamamoto, Kouji
Ikeda, Masafumi
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4125-4125, 1p
Publication Year :: 2023

Full Text Access

Tools